INLURIYO

This brand name is authorized in United States. It is also authorized in Lithuania.

Active ingredients

The drug INLURIYO contains one active pharmaceutical ingredient (API):

`1`	Imlunestrant UNII `9CXQ3PF69U` - IMLUNESTRANT
	Imlunestrant is an antagonist and degrader of wild-type and mutant oestrogen receptor-α (ERα), leading to inhibition of oestrogen receptor-dependent gene transcription and cellular proliferation in ER-positive breast cancer cells.
	Read more about Imlunestrant

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
INLURIYO Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)
INLURIYO Film-coated tablet	MPI, US: SPL/PLR

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
LT	Valstybinė vaistų kontrolės tarnyba	1105719, 1105720, 1105721, 1105723, 1105725, 1105726
US	FDA, National Drug Code	0002-1717

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.